阿莫西林-克拉维酸治疗小鼠败血症模型的体内抗菌作用研究

The in vivo antibacterial activity of amoxicillin-clavulanic acid in mouse septicemia model

目的比较口服阿莫西林-克拉维酸(62.5 mg-15.6 mg)/kg,每日2次给药与每日3次给药方案治疗小鼠败血症的抗菌作用.方法用肺炎链球菌和卡他莫拉菌感染的小鼠败血症模型,给予阿莫西林-克拉维酸(62.5 mg-15.6 mg)/kg,每日2次和3次口服灌胃给药治疗3 d,比较每日2次和每日3次给药的体内抗菌作用.结果对2株肺炎链球菌和2株卡他莫拉菌感染的小鼠败血症模型进行治疗,(62.5 mg-15.6 mg)/kg每日2次组和每日3次组72 h小鼠存活率均为100%,肺组织活菌计数均为0;而生理盐水对照组小鼠存活率均为0,肺组织活菌计数都在106～108 CFU/肺的水平,与给药组差异有显著性(P＜0.001).结论对社区获得性呼吸道感染常见的敏感致病菌如肺炎链球菌、卡他莫拉菌感染,阿莫西林-克拉维酸每日2次与每日3次给药均可达到较好的疗效.

ObjectiveTo evaluate the in vivo antibacterial activity of amoxicillin-clavulanic acid administered orally ( 62.5 mg- 15.6 mg)/kg twice daily versus three times daily.MethodsThe mouse septicemia models were established by challenge of 2 strains of Streptococcus pneumoniae and 2 strains of Moraxella catarrhalis respectively and used for the comparson of antibacterial activity of amoxicillin-clavulanic acid twice a day,three times a day and untreated control group.Results Results showed that after treatment for 72 hours,the survival rates of the two treatment groups were both 100%,the viable CFU in lung tissue being 0.While in the normal saline control group,the survival rate was 0,viable CFU of bacteria in lung tissue ranged from 10 6 to 10 8 CFU/lung,which was significantly higher than that of the treatment groups (P<0.001).ConclusionsAmoxicillin-clavulanic acid (62.5 mg-15.6 mg)/kg given orally,twice a day is as effective as the same dosage three times a day for the treatment of community-acquired respiratory tract infections caused by susceptible pathogens.